Lufotrelvir

Lufotrelvir (PF-07304814), a phosphate proagent of PF-00835231, acts as a potent 3CLpro protease (Mpro) inhibitor with SARS-CoV-2 antiviral activity. Lufotrelvir binds and inhibits SARS-CoV-2 3CLpro activity with a Ki of 174nM. Lufotrelvir is promising single antiviral agent and also can be used for the research of combination with other antivirals that target other critical stages of the coronavirus life cycle.

Product Specifications

CAS Number

[2468015-78-1]

Product Name Alternative

PF-07304814

UNSPSC

12352005

Target

SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/pf-07304814.html

Purity

99.87

Solubility

DMSO : ≥ 100 mg/mL|H2O : 50 mg/mL (ultrasonic)

Smiles

COC1=C(C=C2C(N[C@@H](CC(C)C)C(N[C@H](C(CO[P](O)(O)=O)=O)C[C@H](CCN3)C3=O)=O)=O)C(N2)=CC=C1

Molecular Formula

C24H33N4O9P

Molecular Weight

552.51

References & Citations

[1]Koen Vandyck, et al. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Curr Opin Virol. 2021 Apr 27;49:36-40.|[2]Britton Boras, et al. Title: Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19 Short Title: Novel 3CL Protease Inhibitor for COVID-19